title: Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis.
abstract: There is growing evidence that tyrosine kinase inhibitors (TKIs) may be associated with an increased risk of arterial events. We performed a meta-analysis to estimate the incidence of arterial events in patients with CML treated with TKIs. We identified 29 studies enrolling 15,706 patients. The incidence rates of composite of major arterial events were 0.8 per 100 patient-years for non-TKI treatments, 1.1 per 100 patient-years for dasatinib, 0.1 per 100 patient-years for imatinib, 0.4 per 100 patient-years for bosutinib, 2.8 per 100 patient-years for nilotinib and 10.6 per 100 patient-years for ponatinib. The relative risk (RR) for nilotinib compared with imatinib suggests a significantly increased risk of the composite of major arterial events with nilotinib treatment (RR 5.3; 95%CI 3.0-9.3, p < 0.001). This study demonstrates that, patients who received nilotinib or ponatinib had a greater number of major arterial events when compared to non-TKI-, imatinib-, dasatinib- and bosutinib-treated patients.
authors.affiliation: a Department of Medicine .|b Department of Clinical Epidemiology and Biostatistics , McMaster University , ON , Canada .
authors.forename: Chatree
authors.initials: C
authors.lastname: Chai-Adisaksopha
authors.affiliation: c Department of Medicine , University of Calgary , AB , Canada , and.
authors.forename: Wilson
authors.initials: W
authors.lastname: Lam
authors.affiliation: a Department of Medicine .|d Department of Oncology , McMaster University , ON , Canada.
authors.forename: Christopher
authors.initials: C
authors.lastname: Hillis
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001158:Arteries / Q000187:drug effects* / Q000473:pathology*; D005260:Female; D006801:Humans; D015994:Incidence; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications* / Q000188:drug therapy; D008297:Male; D017202:Myocardial Ischemia / Q000453:epidemiology / Q000209:etiology; D016017:Odds Ratio; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D012306:Risk; D014652:Vascular Diseases / Q000175:diagnosis / Q000453:epidemiology* / Q000209:etiology*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors
keywords: Cerebrovascular disease; chronic myeloid leukemia; coronary artery disease; peripheral arterial disease